Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
-
Ann. Allergy Asthma Immunol. · Feb 2021
Randomized Controlled Trial Multicenter StudyTezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY.
Patients with severe, uncontrolled asthma experience frequent exacerbations and hospitalization, leading to poor health-related quality of life. In the phase 2b PATHWAY study (NCT02054130), tezepelumab reduced exacerbations by up to 71% and improved lung function, asthma control, and health-related quality of life vs placebo. ⋯ Tezepelumab treatment improved PROs vs placebo, as indicated by the higher proportion of ACQ-6 and AQLQ(S)+12 responders and improvements in symptom severity in the tezepelumab dose groups. These data further support the benefits of tezepelumab in patients with severe, uncontrolled asthma.
-
Ann. Allergy Asthma Immunol. · Jul 2018
Randomized Controlled TrialOmalizumab can inhibit respiratory reaction during aspirin desensitization.
Aspirin desensitization has been associated with benefit in management of aspirin-exacerbated respiratory disease (AERD). An intervention that would encourage aspirin desensitization to be performed more frequently has substantial potential for improving outcomes and quality of life in patients with AERD. ⋯ In atopic AERD subjects, omalizumab administration for 16 weeks was associated with "clinically silent" desensitization. Further studies to investigate the therapeutic utility of omalizumab in patients with AERD who are candidates for aspirin desensitization are warranted based on these findings.
-
Ann. Allergy Asthma Immunol. · Jun 2018
Randomized Controlled TrialValidity and responsiveness of the Urticaria Activity and Impact Measure: A new patient-reported tool.
Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, may produce hives, itch, and angioedema. The Urticaria Activity and Impact Measure (U-AIM) is a newly developed 9-item patient-reported measure designed for use in routine clinical practice to assess CSU activity and impact during the previous 7 days. ⋯ The U-AIM is valid and responsive to change and may help clinicians monitor CSU activity and track treatment effectiveness.
-
Ann. Allergy Asthma Immunol. · May 2018
Randomized Controlled Trial Multicenter StudyBenralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Patients with severe asthma can have eosinophilic inflammation and/or allergen sensitization. Benralizumab is an anti-eosinophilic monoclonal antibody indicated for add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. ⋯ Benralizumab treatment decreased exacerbations and improved lung function for patients with severe, uncontrolled eosinophilic asthma regardless of serum IgE concentrations and atopy status.
-
Ann. Allergy Asthma Immunol. · Dec 2015
Randomized Controlled Trial Multicenter Study Clinical TrialTimothy specific IgE levels are associated with efficacy and safety of timothy grass sublingual immunotherapy tablet.
Regional pollen allergen exposure differences may induce variable sensitization profiles that could affect allergen immunotherapy efficacy and safety. ⋯ Sensitization profiles varied by region. Trends toward higher efficacy and increased TRAE incidence in subjects with higher pretreatment Phl p IgE levels were observed.